CSTL — Castle Biosciences Share News
0.000.00%
Last trade - 00:00- $1.03bn
- $776.11m
- $344.23m
U.S. RESEARCH ROUNDUP-Abbvie, Amazon, Illumina
Castle Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Castle Biosciences beats Q2 revenue estimates, hikes forecast
Brief: Castle Biosciences Q2 Revenue USD 103.546 Million Vs. IBES Estimate USD 86.2 Million
U.S. RESEARCH ROUNDUP-Aecom, Humana, Mosaic
Castle Biosciences beats Q1 revenue estimates, raises FY revenue outlook
Brief: Castle Biosciences Q1 Revenue USD 83.679 Million Vs. IBES Estimate USD 79.4 Million
Castle Biosciences Q4 revenue beats expectations
Brief: Castle Biosciences Q4 Revenue USD 87.01 Million Vs. IBES Estimate USD 79 Million
Brief: Castle Biosciences 2025 Total Revenue Expected To Exceed $340 Million
Brief: Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule
Brief: New Data Confirms Performance Of Decisiondx-Melanoma To Identify Patients With Less Than 5% Risk Of Sentinel Lymph Node Positivity
Brief: Scibase And Castle Biosciences Enter Into Loan Agreement Of SEK 20 Million
U.S. RESEARCH ROUNDUP-Affiliated Managers Group, Argenx SE, Cardinal Health Inc
Castle Biosciences' Q3 revenue beats estimates
Brief: Castle Biosciences Q3 Revenue USD 83.043 Million Vs. IBES Estimate USD 71.2 Million
Brief: Castle Biosciences Inc Says Tissuecypher® Provides Actionable Risk Insights That Influence Clinical Management And Prompt Risk-Aligned Intervention In Barrett’s Esophagus
Castle Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Medical testing provider Castle Bio raises annual revenue guidance